Healthcare provider profile · identity verified

Mary-Ann Malik, MD

Internal Medicine · ANTIOCH, CA · NPI 1992883003

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	435	162
Amlodipine Besylate	Amlodipine Besylate	318	121
Losartan Potassium	Losartan Potassium	221	78
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	191	47
Lisinopril	Lisinopril	191	75
Levothyroxine Sodium	Levothyroxine Sodium	151	51
Metformin Hcl Er	Metformin Hcl	146	59
Hydrochlorothiazide	Hydrochlorothiazide	136	50
Atenolol	Atenolol	127	43
Famotidine	Famotidine	120	49
Albuterol Sulfate Hfa	Albuterol Sulfate	112	68
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	112	35
Fluticasone Propionate	Fluticasone Propionate	97	38
Omeprazole	Omeprazole	92	35
Simvastatin	Simvastatin	92	33
Alendronate Sodium	Alendronate Sodium	91	33
Metformin Hcl	Metformin Hcl	90	38
Furosemide	Furosemide	88	28
Metoprolol Tartrate	Metoprolol Tartrate	88	30
Trazodone Hcl	Trazodone Hcl	75	29
Alvesco	Ciclesonide	69	24
Pantoprazole Sodium	Pantoprazole Sodium	66	22
Glipizide	Glipizide	65	26
Ibuprofen	Ibuprofen	59	27
Gabapentin	Gabapentin	53	23
Fluoxetine Hcl	Fluoxetine Hcl	49	14
Glipizide Er	Glipizide	48	21
Allopurinol	Allopurinol	47	19
Jardiance	Empagliflozin	46	18
Lovastatin	Lovastatin	45	16
Metoprolol Succinate	Metoprolol Succinate	45	19
Montelukast Sodium	Montelukast Sodium	45	18
Fluocinonide	Fluocinonide	42	23
Tamsulosin Hcl	Tamsulosin Hcl	42	18
Rosuvastatin Calcium	Rosuvastatin Calcium	41	16
Naproxen	Naproxen	40	14
Terazosin Hcl	Terazosin Hcl	40	14
Hydroxyzine Hcl	Hydroxyzine Hcl	39	14
Cefadroxil	Cefadroxil	34	30
Ozempic	Semaglutide	34	suppressed
Carvedilol	Carvedilol	33	12
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	32	13
Pravastatin Sodium	Pravastatin Sodium	32	12
Pradaxa	Dabigatran Etexilate Mesylate	28	11
Spironolactone	Spironolactone	28	13
Azelastine Hcl	Azelastine Hcl	27	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	27	suppressed
Clopidogrel	Clopidogrel Bisulfate	26	suppressed
Hydralazine Hcl	Hydralazine Hcl	26	12
Baclofen	Baclofen	25	suppressed
Fentanyl	Fentanyl	25	suppressed
Humulin N	Insulin Nph Human Isophane	25	11
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	25	suppressed
Tizanidine Hcl	Tizanidine Hcl	24	14
Oxycodone Hcl	Oxycodone Hcl	23	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	23	suppressed
Potassium Chloride	Potassium Chloride	23	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	23	15
Ciprofloxacin Hcl	Ciprofloxacin Hcl	22	18
Colchicine	Colchicine	22	13
Finasteride	Finasteride	22	suppressed
Sertraline Hcl	Sertraline Hcl	21	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	20	suppressed
Amoxicillin	Amoxicillin	19	17
Nystatin	Nystatin	19	11
Hydrocortisone	Hydrocortisone	18	12
Wixela Inhub	Fluticasone Propion/Salmeterol	18	11
Acyclovir	Acyclovir	17	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	17	14
Eliquis	Apixaban	16	suppressed
Mupirocin	Mupirocin	16	15
Acetaminophen-Codeine	Acetaminophen With Codeine	15	12
Humulin N Kwikpen	Insulin Nph Human Isophane	15	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	14	12
Ketoconazole	Ketoconazole	13	suppressed
Veo Insulin Syringe	Syrge-Ndl,ins 0.3 Ml Half Mark	13	suppressed
Duloxetine Hcl	Duloxetine Hcl	12	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed
Digoxin	Digoxin	11	suppressed
Donepezil Hcl	Donepezil Hcl	11	suppressed
Fenofibrate	Fenofibrate	11	suppressed
Humulin R	Insulin Regular, Human	11	suppressed
Lorazepam	Lorazepam	11	suppressed
Pregabalin	Pregabalin	11	suppressed
Tramadol Hcl	Tramadol Hcl	11	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error